768 A Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Ustekinumab Maintenance Therapy in Moderate - Severe Crohn's Disease Patients: Results From IM-UNITI

Gastroenterology ◽

10.1016/s0016-5085(16)30623-0 ◽

2016 ◽

Vol 150 (4) ◽

pp. S157-S158 ◽

Author(s):

William Sandborn ◽

Brian G. Feagan ◽

Christopher Gasink ◽

Douglas Jacobstein ◽

Long-Long Gao ◽

...

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Maintenance Therapy ◽

Controlled Study ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Sandborn W, Feagan BG, Gasink C, et al (2016) A phase 3 randomized, multicenter, double-blind, placebo-controlled study of ustekinumab maintenance therapy in moderate–severe Crohn’s disease patients: Results from IM-UNITI. Gastroenterology AGA abstract 768

Côlon & Rectum ◽

10.1007/s11725-016-0667-x ◽

2016 ◽

Vol 10 (4) ◽

pp. 260-263

Author(s):

M. Simon

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Maintenance Therapy ◽

Controlled Study ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

OC-057 A PH3 Randomised, Multicenter, Double-Blind, Placebo (PBO)-Controlled Study of Ustekinumab (UST) Maintenance Therapy in Moderate–Severe Crohn’s Disease (CD) PTS: Results from IM-UNITI

Gut ◽

10.1136/gutjnl-2016-312388.56 ◽

2016 ◽

Vol 65 (Suppl 1) ◽

pp. A32.2-A34 ◽

Author(s):

WJ Sandborn ◽

BG Feagan ◽

C Gasink ◽

D Jacobstein ◽

L-L Gao ◽

...

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Maintenance Therapy ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Sa1197 Effects of Vitamin D Supplementation on Intestinal Permeability, Plasma Cathelicidin and Human Beta-Defensin-2 in Crohn's Disease: Results From a Randomised Double-Blind Placebo-Controlled Study

Gastroenterology ◽

10.1016/s0016-5085(13)60803-3 ◽

2013 ◽

Vol 144 (5) ◽

pp. S-226-S-227 ◽

Author(s):

Tara C. Raftery ◽

Adrian Martineau ◽

Claire Greiller ◽

Chun Seng Lee ◽

Deirdre McNamara ◽

...

Keyword(s):

Vitamin D ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Intestinal Permeability ◽

Vitamin D Supplementation ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Sa1198 Vitamin D Supplementation Improves Muscle Strength, Fatigue and Quality of Life in Patients With Crohn's Disease in Remission: Results of a Randomized Double-Blind Placebo-Controlled Study

Gastroenterology ◽

10.1016/s0016-5085(13)60804-5 ◽

2013 ◽

Vol 144 (5) ◽

pp. S-227 ◽

Author(s):

Tara C. Raftery ◽

Martin Healy ◽

Gerry Cox ◽

Deirdre McNamara ◽

Maria O'Sullivan

Keyword(s):

Quality Of Life ◽

Vitamin D ◽

Crohn’S Disease ◽

Muscle Strength ◽

Crohn's Disease ◽

Vitamin D Supplementation ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Restoration of muscle strength after nutritional supplementation in patients with Crohn's disease in a double blind placebo controlled study

Gastroenterology ◽

10.1016/s0016-5085(98)84006-7 ◽

1998 ◽

Vol 114 ◽

pp. A984

Author(s):

B.J. Geerling ◽

C. van Deursen ◽

R.W. Stockbrügger ◽

R-J.M. Brummer

Keyword(s):

Crohn’S Disease ◽

Muscle Strength ◽

Crohn's Disease ◽

Nutritional Supplementation ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

OP014. A multicentre, double-blind, placebo-controlled phase 3 study of ustekinumab, a human interleukins-12/23p40 mab, in moderate-severe Crohn’s disease refractory to anti-tumour necrosis factor α: UNITI-1

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jjw019.013 ◽

2016 ◽

Vol 10 (suppl 1) ◽

pp. S11-S12 ◽

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Tumour Necrosis Factor Α ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Factor Α ◽

Necrosis Factor

Download Full-text

Mo2083 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease

Gastroenterology ◽

10.1053/j.gastro.2012.07.084 ◽

2012 ◽

Vol 143 (3) ◽

pp. e26 ◽

Author(s):

Stephan R. Targan ◽

Brian G. Feagan ◽

Severine Vermeire ◽

Remo Panaccione ◽

Gil Y. Melmed ◽

...

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Does vitamin D supplementation impact plasma cathelicidin, human beta defensin 2 and intestinal permeability in stable Crohn's disease? – Results from a randomised, double blind placebo controlled study

Proceedings of The Nutrition Society ◽

10.1017/s0029665113001997 ◽

2013 ◽

Vol 72 (OCE3) ◽

Author(s):

T. Raftery ◽

A. Martineau ◽

C. Greiller ◽

C. S. Lee ◽

D. McNamara ◽

...

Keyword(s):

Vitamin D ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Intestinal Permeability ◽

Vitamin D Supplementation ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Clinical trial: vitamin D3 treatment in Crohn’s disease - a randomized double-blind placebo-controlled study

Alimentary Pharmacology & Therapeutics ◽

10.1111/j.1365-2036.2010.04355.x ◽

2010 ◽

Vol 32 (3) ◽

pp. 377-383 ◽

Author(s):

S. P. Jørgensen ◽

J. Agnholt ◽

H. Glerup ◽

S. Lyhne ◽

G. E. Villadsen ◽

...

Keyword(s):

Clinical Trial ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

QuANTUM-First: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients (pts) with newly diagnosed (NDx) FLT3-ITD acute myeloid leukemia (AML)

Annals of Oncology ◽

10.1093/annonc/mdx373.046 ◽

2017 ◽

Vol 28 ◽

pp. v370 ◽

Author(s):

R. Schlenk ◽

H. Dombret ◽

S. Amadori ◽

P. Montesinos ◽

M. Levis ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Maintenance Therapy ◽

Myeloid Leukemia ◽

Controlled Study ◽

Newly Diagnosed ◽

Consolidation Chemotherapy ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text